CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
The Effects of Synbiotic Supplementation on Glucose Metabolism and Lipid Profiles in Patients with Diabetes: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors
M. Akbari
Z. Asemi
+5 more
S.T. Heydari
F. Kolahdooz
K.B. Lankarani
M. Moosazadeh
R. Tabrizi
Publication date
1 January 2018
Publisher
Springer New York LLC
Abstract
Although several studies have evaluated the effect of synbiotic intake on metabolic profiles in patients with diabetes, findings are inconsistent. This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to summarize the evidence on the effect of synbiotic intake on metabolic profiles in patients with diabetes. The PubMed, EMBASE, Web of Science, and Cochrane Library databases were systematically searched. All RCTs published up to 12 November 2016 were included. Two review authors independently assessed study eligibility, extracted data, and evaluated risk of bias of included studies. Heterogeneity was measured with a Q test and with I2 statistics. Data were pooled by using the fix or random-effect model based on the heterogeneity test results and expressed as standardized mean difference (SMD) with 95 confidence interval (CI). A total of seven randomized controlled trials were included. Synbiotic consumption significantly changed glucose metabolism, including fasting plasma glucose (FPG) (SMD = �0.29; 95 CI, �0.47, �0.10), insulin concentrations (SMD = �0.84; 95 CI, �1.61, �0.06), homeostasis model assessment of insulin resistance (HOMA-IR) (SMD = �0.80; 95 CI, �1.58, �0.03), homeostatic model assessment-B cell function (HOMA-B) (SMD = �0.36; 95 CI, �0.71, �0.01), quantitative insulin sensitivity check index (QUICKI) (SMD = 0.46; 95 CI, 0.09, 0.82), and significantly improved lipid profiles, such as triglycerides (SMD = �0.36; 95 CI, �0.55, �0.17), very low density lipoprotein-cholesterol (SMD = �0.31; 95 CI, �0.55, �0.08), and total cholesterol (SMD = �0.32; 95 CI, �0.67, �0.03), but had no effect on low density lipoprotein-cholesterol (SMD = �0.07; 95 CI, �0.58, 0.43) and high density lipoprotein-cholesterol concentrations (SMD = �0.25; 95 CI, �0.81, 0.31). Synbiotic may result in an improvement in FPG, insulin, HOMA-IR, HOMA-B, QUICKI, triglycerides, and total cholesterol. © 2017, Springer Science+Business Media, LLC
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
kashan university of medical sciences
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.kaums.ac.ir:3915
Last time updated on 05/05/2019